Results 131 to 140 of about 253,218 (253)

Proteomic Profiling of Myofiber Repair Annexins and Their Role in Duchenne Muscular Dystrophy

PROTEOMICS, Volume 26, Issue 9, Page 6-23, September 2026.
ABSTRACT Myofiber regeneration and membrane repair play crucial roles in maintaining the continuous physiological functioning of the neuromuscular system. A swift and efficient repair mechanism enables the rapid restoration of sarcolemmal integrity following cellular impairment in damaged skeletal muscles.
Paul Dowling, Dounia Bouragba, Elisa Negroni, Capucine Trollet, Margit Zweyer, Dieter Swandulla, Kay Ohlendieck   +6 more
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, Volume 81, Issue 9, Page 3039-3070, September 2026.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
Franziska Roth‐Walter, Ian M. Adcock, Cristina Benito‐Villalvilla, Rodolfo Bianchini, Leif Bjermer, Gaetano Caramori, Luigi Cari, Kian Fan Chung, Zuzana Diamant, Ibon Eguiluz‐Gracia, Edward F. Knol, Milos Jesenak, Francesca Levi‐Schaffer, Giuseppe Nocentini, Liam O'Mahony, Oscar Palomares, Frank Redegeld, Milena Sokolowska, Betty Van Esch, Marco Zurlo, Cristiana Stellato   +20 more
wiley   +1 more source

Powering Neurology Drug Development Trials to Reduce False Negative Results

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Sensitive and reliable measurement of therapeutic outcomes in neurology drug trials remains challenging. Clinical rating scales and their total scores are often considered the gold standard and used as primary efficacy endpoints in studies because of their acceptance by the clinical community and regulators.
Hiromasa Mori, Stig Johan Wiklund, Vikram Ramanarayanan, Fatta B. Nahab   +3 more
wiley   +1 more source

Computer task performance by subjects with Duchenne muscular dystrophy

, 2015
Silvia Regina Pinheiro Malheiros,1 Talita Dias da Silva,2 Francis Meire Favero,2 Luiz Carlos de Abreu,1 Felipe Fregni,3 Denise Cardoso Ribeiro,4 Carlos Bandeira de Mello Monteiro1,4,5 1School of Medicine of ABC, Santo Andre, Brazil; 2Department of ...
Ribeiro DC, Malheiros SRP, Favero FM, de Mello Monteiro CB, da Silva TD, de Abreu LC, Fregni F   +6 more
core  

‘I Do Feel Some Level of Solidarity… in an Individual Way’: Disability Solidarity, Disability Identity and the Role of Social Services

Social Policy &Administration, Volume 60, Issue 5, Page 837-847, September 2026.
ABSTRACT Research on social policy and solidarity often highlights disability as a paradigmatic case of a ‘deserving’ group that warrants social support. However, this hierarchical view of solidarity frequently ignores the role of solidarity in the lived experiences and everyday practices of disabled people themselves.
Roni Holler, Efrat Keidar, Sagit Mor
wiley   +1 more source

Survival in Duchenne muscular dystrophy.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology, 2012
To determine the survival in a population of German patients with Duchenne muscular dystrophy.Information about 94 patients born between 1970 and 1980 was obtained by telephone interviews and questionnaires. In addition to age of death or actual age during the investigation, data concerning clinical course and medical interventions were collected.67 ...
Rall, Susanne, Grimm, Tiemo
openaire   +2 more sources

Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents

, 2011
Steve D Wilton, Sue FletcherCentre for Neuromuscular and Neurological Disorders, University of Western Australia, Crawley, Perth, WA, AustraliaAbstract: The identification of dystrophin and the causative role of mutations in this gene in Duchenne and ...
Steve D Wilton, Sue Fletcher
core  

Proposing a Coverage With Evidence Development Framework for Accelerated Approval at the U.S. Food and Drug Administration

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 9, September 2026.
Dhanush Bearelly, Purav Desai, David T. Zhu, Rajesh Balkrishnan   +3 more
wiley   +1 more source

Erratum: Microdystrophins partially rescue deficits of Duchenne muscular dystrophy iPSC-cardiomyocytes. [PDF]

Mol Ther Adv
Keegan AR, Gonzalez AFGS, Zhang R, Doan H, Torres-Bigio SI, Lau F, Ly KN, Lai EC, Mamuyac LC, Bhimaraju S, Mishra A, Polen MK, Ortiz DS, Lam JH, Eguchi A.   +14 more
europepmc   +1 more source

Beyond the Diagnosis: A Comprehensive Case Report on Duchenne Muscular Dystrophy. [PDF]

Case Rep Crit Care
Shahin MAH, Asiri AA, Alotaibi AS, Majrashi H, Khubrani S, AlQarni SH, Alqurashi SS, Samti ME, AlQarni ZH.   +8 more
europepmc   +1 more source